Dr. Arteaga on Ongoing Trials in Metastatic Breast Cancer

Carlos Arteaga, MD
Published: Tuesday, Aug 09, 2016



Carlos L. Arteaga, MD, associate director for Clinical Research, director, Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, discusses some of the ongoing trials exploring treatments for patients with metastatic breast cancer.

Arteaga mentions ongoing research examining a comparison of anti-estrogen therapy to anti-estrogen plus PI3K-alpha inhibitors. PI3K-alpha inhibitors target the enzyme PI3K-alpha, which is mutated in up to 50% of ER-positive breast cancers.

He also discusses FGF receptor inhibitors and patients with FGFR amplification. Administration of this type of therapy will depend on alterations in the tumor.

Arteaga goes on to briefly discuss ongoing research that is focused on oral anti-estrogen therapies, which have been shown to be beneficial in ER mutations. These types of drugs are also extremely convenient in terms of administration for patients, and they may have better pharmacology than other therapies.


Carlos L. Arteaga, MD, associate director for Clinical Research, director, Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, discusses some of the ongoing trials exploring treatments for patients with metastatic breast cancer.

Arteaga mentions ongoing research examining a comparison of anti-estrogen therapy to anti-estrogen plus PI3K-alpha inhibitors. PI3K-alpha inhibitors target the enzyme PI3K-alpha, which is mutated in up to 50% of ER-positive breast cancers.

He also discusses FGF receptor inhibitors and patients with FGFR amplification. Administration of this type of therapy will depend on alterations in the tumor.

Arteaga goes on to briefly discuss ongoing research that is focused on oral anti-estrogen therapies, which have been shown to be beneficial in ER mutations. These types of drugs are also extremely convenient in terms of administration for patients, and they may have better pharmacology than other therapies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x